董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bernhard R. M. Ehmer | 男 | Director | 62 | 未披露 | 未持股 | 2017-03-30 |
| Ulrich M. Grau | 男 | Director | 68 | 未披露 | 未持股 | 2017-03-30 |
| Berndt Modig | 男 | Director | 58 | 未披露 | 未持股 | 2017-03-30 |
| Ferdinand Verdonck | 男 | Director | 74 | 未披露 | 未持股 | 2017-03-30 |
| Thomas Hecht | 男 | Director | 65 | 未披露 | 未持股 | 2017-03-30 |
| Richard B. Stead | 男 | Director | 64 | 未披露 | 未持股 | 2017-03-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jorg Windisch | 男 | Chief Operating Officer | 46 | 未披露 | 未持股 | 2017-03-30 |
| Adi Hoess | 男 | Chief Executive Officer | 55 | 未披露 | 未持股 | 2017-03-30 |
| Florian Fischer | 男 | Chief Financial Officer | 49 | 未披露 | 未持股 | 2017-03-30 |
董事简历
中英对照 | 中文 | 英文- Bernhard R. M. Ehmer
-
Bernhard R. M. Ehmer自2016年起担任公司监督董事。他自2015年1月起担任Biotest AG管理董事长。在此之前，他曾在Imclone Group（Eli Lilly全资子公司）任职，担任美国地区Imclone Systems Corporation总裁和德国地区总经理。2007/2008年他担任德国Fresenius Biotech首席执行官，在此之前曾担任Merck KGaA, Darmstadt肿瘤业务区域主管和Merck全球临床运营主管。他从1986年到1998年在Boehringer Mannheim德国、意大利和新加坡地区担任多个职位。Boehringer Mannheim持有the University of Heidelberg医学学士学位；并在Academic Teaching Hospital的内科专业工作。
Bernhard R. M. Ehmer has been a member of our supervisory board since 2016. He has been chairman of the board of management of Biotest AG since January 2015. Prior to this, he worked for the Imclone Group, a wholly owned subsidiary of Eli Lilly, as president of Imclone Systems Corporation in the United States and as managing director in Germany. In 2007/2008 he was CEO of Fresenius Biotech, Germany and before this, Dr. Ehmer headed the Business Area Oncology of Merck KGaA, Darmstadt and served as head of Global Clinical Operations at Merck. Between 1986 and 1998 he held various functions at Boehringer Mannheim in Germany, Italy and Singapore. Dr. Ehmer holds a degree in medicine and worked in the Department of Internal Medicine at the Academic Teaching Hospital of the University of Heidelberg. - Bernhard R. M. Ehmer自2016年起担任公司监督董事。他自2015年1月起担任Biotest AG管理董事长。在此之前，他曾在Imclone Group（Eli Lilly全资子公司）任职，担任美国地区Imclone Systems Corporation总裁和德国地区总经理。2007/2008年他担任德国Fresenius Biotech首席执行官，在此之前曾担任Merck KGaA, Darmstadt肿瘤业务区域主管和Merck全球临床运营主管。他从1986年到1998年在Boehringer Mannheim德国、意大利和新加坡地区担任多个职位。Boehringer Mannheim持有the University of Heidelberg医学学士学位；并在Academic Teaching Hospital的内科专业工作。
- Bernhard R. M. Ehmer has been a member of our supervisory board since 2016. He has been chairman of the board of management of Biotest AG since January 2015. Prior to this, he worked for the Imclone Group, a wholly owned subsidiary of Eli Lilly, as president of Imclone Systems Corporation in the United States and as managing director in Germany. In 2007/2008 he was CEO of Fresenius Biotech, Germany and before this, Dr. Ehmer headed the Business Area Oncology of Merck KGaA, Darmstadt and served as head of Global Clinical Operations at Merck. Between 1986 and 1998 he held various functions at Boehringer Mannheim in Germany, Italy and Singapore. Dr. Ehmer holds a degree in medicine and worked in the Department of Internal Medicine at the Academic Teaching Hospital of the University of Heidelberg.
- Ulrich M. Grau
-
Ulrich M. Grau ，从2013年5月到2015年6月，他担任顾问和我们董事会职务。2015年7月他成为我们董事会成员。他有生物技术和制药行业超过30年的经验，包括综合管理、业务发展、企业战略和新产品的开发和技术。从2011年到2012年，他曾是Micromet的首席运营官。在2006年和2010年之间，他曾是Lux Biosciences, Inc.（眼科临床阶段的公司的首席执行官。此前，他担任BASF Pharma/ Knoll的研究与开发总裁，他领导全球研发组织的发展管道，包括Humira。他的事业主要在Aventis Pharma，他最后担任全球后期发展高级副总裁的职务。Lantus 是以他早期在Hoechst AG。担任科学家的发明作为基础的，他获得 the University of Stuttgart的化学和生物化学博士学位。他在担任Purdue University的蛋白质晶体学领域博士后研究员3年。
Ulrich M. Grau served as an advisor to our board from May 2013 until June 2015 and became a board member in July 2015. He has over 30 years of experience in the biotechnology and pharmaceutical industries including general management, business development, corporate strategy and the development of new products and technologies. Dr. Grau was Chief Operating Officer at Micromet from 2011 to 2012. Between 2006 and 2010 Dr. Grau was a founder, President and CEO of Lux Biosciences, Inc., a clinical stage ophthalmic company. Previously, Dr. Grau served as President of Research and Development at BASF Pharma/ Knoll where he directed a global R&D organization whose development pipeline included Humira. The majority of his career was at Aventis Pharma, where he last held the position of senior VP of global late stage development. Lantus® is based on his inventions made during his early years as a scientist with Hoechst AG. Dr. Grau received his Ph.D. in chemistry and biochemistry from the University of Stuttgart and spent three years as a post-doctoral fellow at Purdue University in the field of protein crystallography. - Ulrich M. Grau ，从2013年5月到2015年6月，他担任顾问和我们董事会职务。2015年7月他成为我们董事会成员。他有生物技术和制药行业超过30年的经验，包括综合管理、业务发展、企业战略和新产品的开发和技术。从2011年到2012年，他曾是Micromet的首席运营官。在2006年和2010年之间，他曾是Lux Biosciences, Inc.（眼科临床阶段的公司的首席执行官。此前，他担任BASF Pharma/ Knoll的研究与开发总裁，他领导全球研发组织的发展管道，包括Humira。他的事业主要在Aventis Pharma，他最后担任全球后期发展高级副总裁的职务。Lantus 是以他早期在Hoechst AG。担任科学家的发明作为基础的，他获得 the University of Stuttgart的化学和生物化学博士学位。他在担任Purdue University的蛋白质晶体学领域博士后研究员3年。
- Ulrich M. Grau served as an advisor to our board from May 2013 until June 2015 and became a board member in July 2015. He has over 30 years of experience in the biotechnology and pharmaceutical industries including general management, business development, corporate strategy and the development of new products and technologies. Dr. Grau was Chief Operating Officer at Micromet from 2011 to 2012. Between 2006 and 2010 Dr. Grau was a founder, President and CEO of Lux Biosciences, Inc., a clinical stage ophthalmic company. Previously, Dr. Grau served as President of Research and Development at BASF Pharma/ Knoll where he directed a global R&D organization whose development pipeline included Humira. The majority of his career was at Aventis Pharma, where he last held the position of senior VP of global late stage development. Lantus® is based on his inventions made during his early years as a scientist with Hoechst AG. Dr. Grau received his Ph.D. in chemistry and biochemistry from the University of Stuttgart and spent three years as a post-doctoral fellow at Purdue University in the field of protein crystallography.
- Berndt Modig
-
Berndt Modig自2015年3月起担任董事会成员。自2016年3月以来，Modig一直担任Pharvaris N.V.的首席执行官，这是一家专注于罕见病的公共临床阶段生物技术公司。从2010年3月起，他担任制药公司Prosensa Holding N.V.的首席财务官，直到2015年1月被BioMarin pharmaceutical Inc.收购。2003年10月至2008年11月，Modig先生担任制药公司Jerini AG的首席财务官，负责私人融资、2005年首次公开募股，并于2008年被Takeda pharmaceutical company收购的生物制药公司Shire plc收购。在此之前，Modig先生于2001年至2003年担任二手工业设备分销商Surplex AG的首席财务官，并于1999年至2001年在总部位于美国的热塑性阀门制造商Hayward Industrial Products Inc.担任欧洲财务总监。Modig先生曾于1994年至1999年担任总部位于Brussels的私募股权公司Agra Industria的合伙人，1991年至1994年担任纽约Financial Services Industry Group of Price Waterhouse LLP的高级经理。Modig目前担任公共临床阶段生物技术公司Pharvaris N.V.的董事。他还担任审计委员会主席和上市生物制药公司Centogene N.V.的董事。此前，他还曾担任(i) Kiadis Pharma n.v.(一家上市生物制药公司)的董事会(2016年6月至2021年4月);(ii) Auris Medical Holding Ltd.(一家制药公司)的董事会(2014年4月至2018年3月);(iii) Affimed n.v.(一家上市生物制药公司)的董事会(2014年9月至2020年8月)。他持有University of Lund的工商管理、经济学和德语学士学位，以及INSEAD, Fontainebleau, France的工商管理硕士学位。他是注册会计师(不活跃)。
Berndt Modig has served as a member of the Board since March 2015. Since March 2016 Mr. Modig has served as Chief Executive Officer of Pharvaris N.V., a public clinical stage biotechnology company focusing on rare diseases. He served as Chief Financial Officer of Prosensa Holding N.V., a pharmaceutical company, from March 2010 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015. From October 2003 to November 2008 Mr. Modig was Chief Financial Officer at Jerini AG, a pharmaceutical company, where he directed private financing rounds, its initial public offering in 2005 and its acquisition by Shire plc, a biopharmaceutical company acquired by Takeda Pharmaceutical Company, in 2008. Before that, Mr. Modig served as Chief Financial Officer at Surplex AG, a reseller of used industrial equipment, from 2001 to 2003 and as Finance Director Europe of U.S.-based Hayward Industrial Products Inc., a thermoplastic valve manufacturer, from 1999 to 2001. In previous positions, Mr. Modig was a partner in the Brussels-based private equity firm Agra Industria from 1994 to 1999 and a Senior Manager in the Financial Services Industry Group of Price Waterhouse LLP in New York from 1991 to 1994. Mr. Modig currently serves as a director of Pharvaris N.V., a public clinical stage biotechnology company. He also serves as chair of the audit committee and as a director of Centogene N.V., a public biopharmaceutical company. He also previously served on (i) the board of directors of Kiadis Pharma N.V., a public biopharmaceutical company, from June 2016 to April 2021 (ii) the board of directors of Auris Medical Holding Ltd., a pharmaceutical company, from April 2014 to March 2018 and (iii) the board of directors of Affimed N.V., a public biopharmaceutical company, from September 2014 to August 2020. Mr. Modig received his bachelor's degree in business administration, economics and German from the University of Lund, Sweden and his M.B.A. from INSEAD, Fontainebleau, France and is a Certified Public Accountant (inactive). - Berndt Modig自2015年3月起担任董事会成员。自2016年3月以来，Modig一直担任Pharvaris N.V.的首席执行官，这是一家专注于罕见病的公共临床阶段生物技术公司。从2010年3月起，他担任制药公司Prosensa Holding N.V.的首席财务官，直到2015年1月被BioMarin pharmaceutical Inc.收购。2003年10月至2008年11月，Modig先生担任制药公司Jerini AG的首席财务官，负责私人融资、2005年首次公开募股，并于2008年被Takeda pharmaceutical company收购的生物制药公司Shire plc收购。在此之前，Modig先生于2001年至2003年担任二手工业设备分销商Surplex AG的首席财务官，并于1999年至2001年在总部位于美国的热塑性阀门制造商Hayward Industrial Products Inc.担任欧洲财务总监。Modig先生曾于1994年至1999年担任总部位于Brussels的私募股权公司Agra Industria的合伙人，1991年至1994年担任纽约Financial Services Industry Group of Price Waterhouse LLP的高级经理。Modig目前担任公共临床阶段生物技术公司Pharvaris N.V.的董事。他还担任审计委员会主席和上市生物制药公司Centogene N.V.的董事。此前，他还曾担任(i) Kiadis Pharma n.v.(一家上市生物制药公司)的董事会(2016年6月至2021年4月);(ii) Auris Medical Holding Ltd.(一家制药公司)的董事会(2014年4月至2018年3月);(iii) Affimed n.v.(一家上市生物制药公司)的董事会(2014年9月至2020年8月)。他持有University of Lund的工商管理、经济学和德语学士学位，以及INSEAD, Fontainebleau, France的工商管理硕士学位。他是注册会计师(不活跃)。
- Berndt Modig has served as a member of the Board since March 2015. Since March 2016 Mr. Modig has served as Chief Executive Officer of Pharvaris N.V., a public clinical stage biotechnology company focusing on rare diseases. He served as Chief Financial Officer of Prosensa Holding N.V., a pharmaceutical company, from March 2010 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015. From October 2003 to November 2008 Mr. Modig was Chief Financial Officer at Jerini AG, a pharmaceutical company, where he directed private financing rounds, its initial public offering in 2005 and its acquisition by Shire plc, a biopharmaceutical company acquired by Takeda Pharmaceutical Company, in 2008. Before that, Mr. Modig served as Chief Financial Officer at Surplex AG, a reseller of used industrial equipment, from 2001 to 2003 and as Finance Director Europe of U.S.-based Hayward Industrial Products Inc., a thermoplastic valve manufacturer, from 1999 to 2001. In previous positions, Mr. Modig was a partner in the Brussels-based private equity firm Agra Industria from 1994 to 1999 and a Senior Manager in the Financial Services Industry Group of Price Waterhouse LLP in New York from 1991 to 1994. Mr. Modig currently serves as a director of Pharvaris N.V., a public clinical stage biotechnology company. He also serves as chair of the audit committee and as a director of Centogene N.V., a public biopharmaceutical company. He also previously served on (i) the board of directors of Kiadis Pharma N.V., a public biopharmaceutical company, from June 2016 to April 2021 (ii) the board of directors of Auris Medical Holding Ltd., a pharmaceutical company, from April 2014 to March 2018 and (iii) the board of directors of Affimed N.V., a public biopharmaceutical company, from September 2014 to August 2020. Mr. Modig received his bachelor's degree in business administration, economics and German from the University of Lund, Sweden and his M.B.A. from INSEAD, Fontainebleau, France and is a Certified Public Accountant (inactive).
- Ferdinand Verdonck
-
Ferdinand Verdonck，自2012年7月起，担任董事长；从2007年4月至2012年7月，担任AMT监事会主席。他 J.P. Morgan European Investment Trust, Groupe SNEF, Laco Information Services 以及 Virtus Funds的董事会成员。从1992到2003年，他是Almanij NV公司总经理，这是一家已与KBC公司合并了的金融服务公司，他的职责合并包括公司战略、财务管理、行政管理和公司治理的监督，包括参与许多国家的上市和私人持有的公司董事会。他担任在比利时的两个生物技术公司Belgium, Movetis 以及 Galapagos的审计委员会主席以及董事会成员。他也曾担任 Banco Urquijo的董事长、 Dictaphone Corporation的董事、比利时和卢森堡的Dutch Chamber of Commerce的董事、鲁汶根特管理学院（Vlerick Leuven Ghent Management School）的总经理之一以及其审计委员会主席。 Verdonck先生拥有鲁汶大学（KU Leuven）的法律学士学位和经济学学士学位，和芝加哥大学（University of Chicago）的经济学学士学位。
Ferdinand Verdonck has been a member of our supervisory board since July 2014. He is a director and a member of the Audit Committee of Virtus Funds and Laco Information Services. In recent years he was director of Groupe SNEF, director and member of the audit committee of J.P. Morgan European Investment Trust and director and chairman of the audit committee of biotechnology companies: uniQure N.V. in the Netherlands and Movetis and Galapagos in Belgium. He has previously served as chairman of Banco Urquijo and of Nasdaq Europe and as a director of Dictaphone Corporation. From 1992 to 2003 he was the managing director of Almanij NV, a financial services company which has since merged with KBC, and his responsibilities included company strategy, financial control, supervision of executive management and corporate governance, including board participation in publicly-traded and privately-held companies in many countries. Mr. Verdonck holds a law degree from KU Leuven and degrees in economics from KU Leuven and the University of Chicago. - Ferdinand Verdonck，自2012年7月起，担任董事长；从2007年4月至2012年7月，担任AMT监事会主席。他 J.P. Morgan European Investment Trust, Groupe SNEF, Laco Information Services 以及 Virtus Funds的董事会成员。从1992到2003年，他是Almanij NV公司总经理，这是一家已与KBC公司合并了的金融服务公司，他的职责合并包括公司战略、财务管理、行政管理和公司治理的监督，包括参与许多国家的上市和私人持有的公司董事会。他担任在比利时的两个生物技术公司Belgium, Movetis 以及 Galapagos的审计委员会主席以及董事会成员。他也曾担任 Banco Urquijo的董事长、 Dictaphone Corporation的董事、比利时和卢森堡的Dutch Chamber of Commerce的董事、鲁汶根特管理学院（Vlerick Leuven Ghent Management School）的总经理之一以及其审计委员会主席。 Verdonck先生拥有鲁汶大学（KU Leuven）的法律学士学位和经济学学士学位，和芝加哥大学（University of Chicago）的经济学学士学位。
- Ferdinand Verdonck has been a member of our supervisory board since July 2014. He is a director and a member of the Audit Committee of Virtus Funds and Laco Information Services. In recent years he was director of Groupe SNEF, director and member of the audit committee of J.P. Morgan European Investment Trust and director and chairman of the audit committee of biotechnology companies: uniQure N.V. in the Netherlands and Movetis and Galapagos in Belgium. He has previously served as chairman of Banco Urquijo and of Nasdaq Europe and as a director of Dictaphone Corporation. From 1992 to 2003 he was the managing director of Almanij NV, a financial services company which has since merged with KBC, and his responsibilities included company strategy, financial control, supervision of executive management and corporate governance, including board participation in publicly-traded and privately-held companies in many countries. Mr. Verdonck holds a law degree from KU Leuven and degrees in economics from KU Leuven and the University of Chicago.
- Thomas Hecht
-
Thomas Hecht，2007年以来，他担任我们监事会主席。他是瑞士屈斯纳赫特 的Hecht Healthcare Consulting（2002年创办的生物制药咨询公司）的负责人。他担任Cell Medica Ltd., Delenex AG 的董事长和 SuppreMol GmbH监事会主席以及Humabs BioMed AG董事。他曾是Amgen Europe的营销副总裁。从1989年到2002年，作为一位经验丰富的经理和行业专业人士，他在 Amgen担任各种临床开发职位并不断被提拔。加入生物制药行业之前，他在内科医学认证医师，他担任德国the University of Freiburg的Program for Bone Marrow Transplantation联合负责人。
Thomas Hecht has been the chairman of our supervisory board since 2007. He is head of Hecht Healthcare Consulting in Küssnacht, Switzerland, a biopharmaceutical consulting company founded in 2002. Dr. Hecht also serves as chairman of the board of directors of Cell Medica Ltd., Vaximm AG and as a director of Humabs BioMed AG. Until the beginning of March 2015 he served as chairman of the supervisory council of SuppreMol GmbH and until June 2016 of Delenex AG. Dr. Hecht was previously Vice President Marketing at Amgen Europe. A seasoned manager and industry professional, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, he was certified in internal medicine and served as Co-Head of the Program for Bone Marrow Transplantation at the University of Freiburg, Germany. - Thomas Hecht，2007年以来，他担任我们监事会主席。他是瑞士屈斯纳赫特 的Hecht Healthcare Consulting（2002年创办的生物制药咨询公司）的负责人。他担任Cell Medica Ltd., Delenex AG 的董事长和 SuppreMol GmbH监事会主席以及Humabs BioMed AG董事。他曾是Amgen Europe的营销副总裁。从1989年到2002年，作为一位经验丰富的经理和行业专业人士，他在 Amgen担任各种临床开发职位并不断被提拔。加入生物制药行业之前，他在内科医学认证医师，他担任德国the University of Freiburg的Program for Bone Marrow Transplantation联合负责人。
- Thomas Hecht has been the chairman of our supervisory board since 2007. He is head of Hecht Healthcare Consulting in Küssnacht, Switzerland, a biopharmaceutical consulting company founded in 2002. Dr. Hecht also serves as chairman of the board of directors of Cell Medica Ltd., Vaximm AG and as a director of Humabs BioMed AG. Until the beginning of March 2015 he served as chairman of the supervisory council of SuppreMol GmbH and until June 2016 of Delenex AG. Dr. Hecht was previously Vice President Marketing at Amgen Europe. A seasoned manager and industry professional, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, he was certified in internal medicine and served as Co-Head of the Program for Bone Marrow Transplantation at the University of Freiburg, Germany.
- Richard B. Stead
-
Richard B. Stead，2007年以来，他担任我们监事会成员。他有在生物技术和制药行业，设计和指导临床试验，管理策略和授权的活动的超过25年的经验。他目前是BioPharma Consulting Services的创始人和负责人，他在那里参与了许多肿瘤产品的开发，包括癌症免疫疗法的不同策略。此前，他是Immunex Corporation副总裁，负责肿瘤和神经学产品开发。他担任临床开发的不同职位并在Amgen的前2个产品 Epogen和Neupogen的FDA批准和商业化发挥了关键作用。他毕业于威斯康辛大学（University of Wisconsin）并获得斯坦福大学（Stanford University）医学博士学位。他完成了Harvard Medical School和Brigham and Women’s Hospital实习医师和住院医师职务并完成奖学金。随后他进行在the National Cancer institute分子生物学实验室的博士后研究。他也在Ascend Biopharmaceuticals Ltd和the Seattle Reparatory Theatre的董事会任职。
Richard B. Stead has been a member of our supervisory board since 2007. He has more than 25 years of experience in the biotechnology and pharmaceutical industries, designing and directing clinical trials, regulatory strategy and licensing activities. He is currently Founder and Principal of BioPharma Consulting Services, where he is involved in the development of a number of oncology products including different strategies for cancer immunotherapy. Previously, he was Vice President, Clinical Research of Immunex Corporation, responsible for oncology and neurology product development. Dr. Stead has served in various positions in clinical development and played a key role in the FDA approval and commercialization of Amgen’s first two products, Epogen and Neupogen. Dr. Stead graduated from the University of Wisconsin and earned an M.D. from Stanford University. He completed his internship and residency as well as a fellowship in Hematology at Harvard Medical School and the Brigham and Women’s Hospital followed by post-doctoral research in the Laboratory of Molecular Biology at the National Cancer institute. He also serves on the boards of Ascend Biopharmaceuticals Ltd. and the Seattle Reparatory Theatre. - Richard B. Stead，2007年以来，他担任我们监事会成员。他有在生物技术和制药行业，设计和指导临床试验，管理策略和授权的活动的超过25年的经验。他目前是BioPharma Consulting Services的创始人和负责人，他在那里参与了许多肿瘤产品的开发，包括癌症免疫疗法的不同策略。此前，他是Immunex Corporation副总裁，负责肿瘤和神经学产品开发。他担任临床开发的不同职位并在Amgen的前2个产品 Epogen和Neupogen的FDA批准和商业化发挥了关键作用。他毕业于威斯康辛大学（University of Wisconsin）并获得斯坦福大学（Stanford University）医学博士学位。他完成了Harvard Medical School和Brigham and Women’s Hospital实习医师和住院医师职务并完成奖学金。随后他进行在the National Cancer institute分子生物学实验室的博士后研究。他也在Ascend Biopharmaceuticals Ltd和the Seattle Reparatory Theatre的董事会任职。
- Richard B. Stead has been a member of our supervisory board since 2007. He has more than 25 years of experience in the biotechnology and pharmaceutical industries, designing and directing clinical trials, regulatory strategy and licensing activities. He is currently Founder and Principal of BioPharma Consulting Services, where he is involved in the development of a number of oncology products including different strategies for cancer immunotherapy. Previously, he was Vice President, Clinical Research of Immunex Corporation, responsible for oncology and neurology product development. Dr. Stead has served in various positions in clinical development and played a key role in the FDA approval and commercialization of Amgen’s first two products, Epogen and Neupogen. Dr. Stead graduated from the University of Wisconsin and earned an M.D. from Stanford University. He completed his internship and residency as well as a fellowship in Hematology at Harvard Medical School and the Brigham and Women’s Hospital followed by post-doctoral research in the Laboratory of Molecular Biology at the National Cancer institute. He also serves on the boards of Ascend Biopharmaceuticals Ltd. and the Seattle Reparatory Theatre.
高管简历
中英对照 | 中文 | 英文- Jorg Windisch
Jorg Windisch，他于2016年加入我们。此前，他在Sandoz Biopharmaceuticals（一个 Novartis公司）任职20年，最后担任其首席科学官。1996年他加入Novartis（Sandoz的生物制剂部门），他担任Somatropin （Omnitrope ，有史以来第一次生物仿制药）、Sandoz’ Epoetinalfa （Binocrit ）和Filgrastim （Zarzio ） 产品的领导职务。在过去的15年里，他建立了一个生物国际技术开发组织和五年他为Novartis Pharma and Sandoz领导联合生物制品的技术开发和生产组织5年。他从事大约20个生物制剂开发和制造，目前在市场上的有六个。他曾在奥地利、德国和美国学习。他获得the University of Innsbruck的生物化学和细胞基因博士学位。
Jorg Windisch joined us in 2016 after spending 20 years at Sandoz Biopharmaceuticals a Novartis company, most recently serving as Chief Science Officer. He joined Novartis in 1996 in the biologics unit of Sandoz, where he played a leading role in the development of Somatropin (Omnitrope®), the first ever biosimilar medicine, as well as of Sandoz’ Epoetinalfa (Binocrit®) and Filgrastim (Zarzio®) products. Over the course of 15 years he built an international technical development organization for biologics and for five years Dr. Windisch also led the joint biologics technical development and manufacturing organization for Novartis Pharma and Sandoz. He was involved in the development and manufacturing of about 20 biologics, six of which are currently marketed. Dr. Windisch was educated in Austria, Germany and the U.S. and received his Ph.D. in Biochemistry and Molecular Genetics from the University of Innsbruck. In March 2017 we entered into a termination agreement with Dr. Windisch, who will be leaving the Company at the end of June 2017. He will continue to support Affimed as a consulting expert following his departure.- Jorg Windisch，他于2016年加入我们。此前，他在Sandoz Biopharmaceuticals（一个 Novartis公司）任职20年，最后担任其首席科学官。1996年他加入Novartis（Sandoz的生物制剂部门），他担任Somatropin （Omnitrope ，有史以来第一次生物仿制药）、Sandoz’ Epoetinalfa （Binocrit ）和Filgrastim （Zarzio ） 产品的领导职务。在过去的15年里，他建立了一个生物国际技术开发组织和五年他为Novartis Pharma and Sandoz领导联合生物制品的技术开发和生产组织5年。他从事大约20个生物制剂开发和制造，目前在市场上的有六个。他曾在奥地利、德国和美国学习。他获得the University of Innsbruck的生物化学和细胞基因博士学位。
- Jorg Windisch joined us in 2016 after spending 20 years at Sandoz Biopharmaceuticals a Novartis company, most recently serving as Chief Science Officer. He joined Novartis in 1996 in the biologics unit of Sandoz, where he played a leading role in the development of Somatropin (Omnitrope®), the first ever biosimilar medicine, as well as of Sandoz’ Epoetinalfa (Binocrit®) and Filgrastim (Zarzio®) products. Over the course of 15 years he built an international technical development organization for biologics and for five years Dr. Windisch also led the joint biologics technical development and manufacturing organization for Novartis Pharma and Sandoz. He was involved in the development and manufacturing of about 20 biologics, six of which are currently marketed. Dr. Windisch was educated in Austria, Germany and the U.S. and received his Ph.D. in Biochemistry and Molecular Genetics from the University of Innsbruck. In March 2017 we entered into a termination agreement with Dr. Windisch, who will be leaving the Company at the end of June 2017. He will continue to support Affimed as a consulting expert following his departure.
- Adi Hoess
Adi Hoess，他于2010年10月加入我们并担任首席商务官。2011年9月以来，他担任我们首席执行官。他有20多年的综合管理、业务发展、产品商业化、融资和并购的专业经验。在加入我们之前，他担任Jerini AG首席商务官和Jenowis AG的首席执行官。在Jerini AG，他负责业务开发，市场营销和销售和Firazyr的市场引入。他在Shire Pharmaceuticals收购Jerini期间发挥了重要作用。他于1993年在 MorphoSys。开始他的职业生涯。1991年他获得了University of Munich的化学和生物化学博士学位。1997年他获得the Technical University of Munich的医学博士学位。
Adi Hoess joined us in October 2010 as Chief Commercial Officer and since September 2011 has served as our Chief Executive Officer. He has more than 20 years of professional experience with an extensive background in general management, business development, product commercialization, fund raising and M&A. Prior to joining us, Dr. Hoess was Chief Commercial Officer at Jerini AG and Chief Executive Officer of Jenowis AG. At Jerini AG he was responsible for business development, marketing and sales and the market introduction of Firazyr. He also played a major role in the sale of Jerini to Shire plc. Dr. Hoess began his professional career in 1993 at MorphoSys. Dr. Hoess received his Ph.D. in chemistry and biochemistry from the University of Munich in 1991 and an M.D. from the Technical University of Munich in 1997.- Adi Hoess，他于2010年10月加入我们并担任首席商务官。2011年9月以来，他担任我们首席执行官。他有20多年的综合管理、业务发展、产品商业化、融资和并购的专业经验。在加入我们之前，他担任Jerini AG首席商务官和Jenowis AG的首席执行官。在Jerini AG，他负责业务开发，市场营销和销售和Firazyr的市场引入。他在Shire Pharmaceuticals收购Jerini期间发挥了重要作用。他于1993年在 MorphoSys。开始他的职业生涯。1991年他获得了University of Munich的化学和生物化学博士学位。1997年他获得the Technical University of Munich的医学博士学位。
- Adi Hoess joined us in October 2010 as Chief Commercial Officer and since September 2011 has served as our Chief Executive Officer. He has more than 20 years of professional experience with an extensive background in general management, business development, product commercialization, fund raising and M&A. Prior to joining us, Dr. Hoess was Chief Commercial Officer at Jerini AG and Chief Executive Officer of Jenowis AG. At Jerini AG he was responsible for business development, marketing and sales and the market introduction of Firazyr. He also played a major role in the sale of Jerini to Shire plc. Dr. Hoess began his professional career in 1993 at MorphoSys. Dr. Hoess received his Ph.D. in chemistry and biochemistry from the University of Munich in 1991 and an M.D. from the Technical University of Munich in 1997.
- Florian Fischer
Florian Fischer，他于2005年加入我们并担任兼职首席财务官并不断被提拔。2014年1月1日以来，他以在我们公司任职95年。他是MedVenture Partners（总部位于慕尼黑的公司财务和战略咨询公司，专注于生命科学和医疗保健行业）的创始人兼首席执行官。从2002年到2011年，他担任Activaero GmbH 的首席财务官。2011年以来，他一直参与公司发展。从2008年到2013年，他还担任Vivendy Ltd的首席财务官。2009年他担任AbCheck的董事总经理。MedVenture Partners成立之前，他在KPMG工作了六年多，直到2002年他负责生物技术和医疗保健任务。在加入KPMG之前，他在德意志银行（Deutsche Bank AG）工作。他也是Amphivena审计委员会的一员。他获得Humboldt University的工商管理研究生学位和the University of Bielefeld的公共卫生博士学位。
Florian Fischer joined us in 2005 as Chief Financial Officer on a part-time basis, which has increased over time to a full time position since September 2014. Dr. Fischer is founder and Chief Executive Officer of MedVenture Partners, a Munich-based corporate finance and strategy advisory company focusing on the life sciences and health care industry. Dr. Fischer was the Chief Financial Officer of Activaero GmbH from 2002 until 2011 and has been involved with corporate development since 2011. He also served as the Chief Financial Officer of Vivendy Ltd. from 2008 until 2013 and as a managing director of AbCheck in 2009. Prior to founding MedVenture Partners, Dr. Fischer worked with KPMG for more than six years until 2002 where he was responsible for biotech and healthcare assignments. Before joining KPMG, he worked for Deutsche Bank AG. Dr. Fischer is also a director of Amphivena. He holds a graduate degree in business administration from Humboldt University, Berlin and a Ph.D. in public health from the University of Bielefeld.- Florian Fischer，他于2005年加入我们并担任兼职首席财务官并不断被提拔。2014年1月1日以来，他以在我们公司任职95年。他是MedVenture Partners（总部位于慕尼黑的公司财务和战略咨询公司，专注于生命科学和医疗保健行业）的创始人兼首席执行官。从2002年到2011年，他担任Activaero GmbH 的首席财务官。2011年以来，他一直参与公司发展。从2008年到2013年，他还担任Vivendy Ltd的首席财务官。2009年他担任AbCheck的董事总经理。MedVenture Partners成立之前，他在KPMG工作了六年多，直到2002年他负责生物技术和医疗保健任务。在加入KPMG之前，他在德意志银行（Deutsche Bank AG）工作。他也是Amphivena审计委员会的一员。他获得Humboldt University的工商管理研究生学位和the University of Bielefeld的公共卫生博士学位。
- Florian Fischer joined us in 2005 as Chief Financial Officer on a part-time basis, which has increased over time to a full time position since September 2014. Dr. Fischer is founder and Chief Executive Officer of MedVenture Partners, a Munich-based corporate finance and strategy advisory company focusing on the life sciences and health care industry. Dr. Fischer was the Chief Financial Officer of Activaero GmbH from 2002 until 2011 and has been involved with corporate development since 2011. He also served as the Chief Financial Officer of Vivendy Ltd. from 2008 until 2013 and as a managing director of AbCheck in 2009. Prior to founding MedVenture Partners, Dr. Fischer worked with KPMG for more than six years until 2002 where he was responsible for biotech and healthcare assignments. Before joining KPMG, he worked for Deutsche Bank AG. Dr. Fischer is also a director of Amphivena. He holds a graduate degree in business administration from Humboldt University, Berlin and a Ph.D. in public health from the University of Bielefeld.